Recent events
Recent events tied to this brand in public sources.
Back to profile63 entries · Page 1 of 4
2026
Bayer raises 2026 adjusted EBITDA outlook
Bayer raised its 2026 outlook for currency-adjusted EBITDA before special items, citing stronger pharmaceutical performance in the first nine months of the year.
2026
Bayer raises outlook after pharma recovery
A WSJ headline reports that Bayer raised its outlook after a recovery in its pharma business; the supplied source does not provide further details.
2026
Monsanto secures defense verdict in Roundup trial
A Missouri jury returned a unanimous defense verdict in Monsanto's favor in a Roundup-related trial involving claims of design defect, fraud and negligence.
2026
Jury rules for Bayer in Roundup cancer trial
A St. Louis jury unanimously ruled for Bayer-owned Monsanto in a trial over claims that Roundup caused cancer. Bayer denied the claims.
2026
Jury rules for Bayer in Roundup cancer trial
A Missouri jury unanimously sided with Bayer in a trial over claims that Roundup caused cancer in three women. The women had alleged that they developed non-Hodgkin lymphoma after regularly using the weedkiller.
2026
Phylo and Bayer announce AI drug-discovery research partnership
Phylo announced a partnership with Bayer to use Phylo’s Biomni Lab AI platform in drug-discovery research, including workflows aimed at assembling scientific literature and omics evidence. The announcement was unclear about whether Bayer’s access had begun.
2026
Bayer CEO cut managers by 70%
Fortune reports that Bayer's CEO has cut the number of managers at the company by 70%, with the article indicating the company now faces the next stage of the effort.
2026
Bayer to build $2.2 billion drug manufacturing plant in New Albany
Pharmaceutical company Bayer plans to build a $2.2 billion drug manufacturing plant in New Albany, as reported by wosu.org.
2022
Bayer announces sale of its Environmental Science Professional business
Bayer said it is selling its Environmental Science Professional business to private equity firm Cinven for $2.6 billion. The sale was expected to close in the second half of 2022.
2022
Lawsuit alleges defects in Bayer's Essure device
A plaintiff sued Bayer and related entities, alleging that defects in the Essure birth control device and its manufacturing could harm users. The allegations are described in the complaint; the article does not report a court determination.
2022
Los Angeles files PCB contamination lawsuit against Monsanto
The city of Los Angeles sued Monsanto and two other companies seeking compensation for past and future costs related to PCB contamination of waterways. The city alleges that PCBs continue to enter local waterways and soils. Bayer said it was reviewing the lawsuit and believed it was without merit, and denied that Monsanto manufactured, used, or disposed of PCBs in Los Angeles waters.
2022
Bayer and Janssen sue Micro Labs over Xarelto patents
Bayer Pharma AG, Bayer AG, and Janssen Pharmaceuticals Inc. filed a patent-infringement case against Micro Labs LTD and Micro Labs USA Inc. concerning Xarelto. The plaintiffs seek declaratory and injunctive relief and expenses.
2022
Bayer discontinues development of eliapixant
Bayer decided to discontinue clinical development of eliapixant, an investigational P2X3 receptor antagonist. Evotec said it regained rights to all P2X3 assets and would evaluate the data when available.
2022
Bayer launches Testing4Ag platform
Bayer launched Testing4Ag, a programme through which research scientists worldwide can submit novel chemistries to Bayer for testing for potential new ways to control fungal diseases, insect pests or weeds. Bayer says the programme provides testing and results to participants while they retain rights to potential intellectual property generated through the programme.
2021
Bayer and SAME Foundation launch COVID-19 relief fund
Bayer South East Africa launched a COVID-19 relief fund in partnership with the South Africa Medical and Education (SAME) Foundation to provide equipment and psychological support to healthcare workers.
2021
Crystal Crop completes acquisition of four Bayer hybrid seed businesses
Crystal Crop Protection completed its acquisition from Bayer in India of four hybrid seed businesses: cotton, mustard, pearl millet and grain sorghum. The acquired business includes the Proagro and Surpass brands.
2021
Jury awards $62 million in PCB exposure case
A King County jury awarded $62 million in damages to eight people harmed by exposure to PCBs at Sky Valley Education Center. The jury decided Bayer had done too little to warn the public about PCBs. Bayer Pharmaceuticals said it disagreed with the verdict and planned to appeal.
2021
Huma and Bayer collaborate on lung cancer research
Huma and Bayer announced a collaboration using machine learning to help distinguish types of non-small-cell lung cancer from CT scans and improve diagnosis.
2021
EarthOptics closes $10.3 million Series A funding round
EarthOptics closed its Series A investment round, raising an additional $10.3 million. Leaps by Bayer led the round, with Bayer and other investors also participating.
2021
FDA approves Astepro for nonprescription sale
The U.S. Food and Drug Administration approved Bayer's Astepro nasal spray for sale without a prescription.